Muhammad Farhan, MD
Nephrology · Mt Sterling, KYNPI 1962748541
Payments from drug & device makers
Across 671 payments — averaging $18.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- AstraZeneca$1K
- Amgen$1K
- AbbVie$1K
- GSK$751
- Bayer$718
- plus $6K from 45 others
What the payments were for
- Travel & lodging$1,31811%
- Food & beverage$10,84287%
- Education$3593%
- Entertainment$160%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 770G$555
- MEDTRONIC REUSABLE INSTRUMENTS$514
- FARXIGA$273
- BREZTRI$273
- LOKELMA$267
- Kerendia$125
- JARDIANCE$107
- KRYSTEXXA$100
How this compares
$12,534 in reported general payments places this provider in the 90th percentile of 165 nephrology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JynarqueTolvaptan | 12 | $232,764 |
| OzempicSemaglutide | 209 | $220,209 |
| EliquisApixaban | 266 | $169,766 |
| FarxigaDapagliflozin Propanediol | 195 | $131,770 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 122 | $86,759 |
| JanuviaSitagliptin Phosphate | 98 | $86,652 |
| JardianceEmpagliflozin | 104 | $79,782 |
| VraylarCariprazine Hcl | 47 | $67,380 |
| ZenpepLipase/Protease/Amylase | 26 | $41,294 |
| XphozahTenapanor Hcl | 11 | $38,326 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 50 | $37,640 |
| KerendiaFinerenone | 42 | $35,480 |
| XifaxanRifaximin | 11 | $35,320 |
| LokelmaSodium Zirconium Cyclosilicate | 44 | $34,992 |
| LinzessLinaclotide | 43 | $27,324 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Jynarque | $697 | $232,76412 claims |
| Novo NordiskOzempic | $382 | $220,209209 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Lokelma | $1,387 | $204,403289 claims |
| PfizerEliquis | $587 | $169,766266 claims |
| AbbVieVraylar, Linzess, Qulipta | $1,053 | $107,306101 claims |
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat | $201 | $106,042145 claims |
| MerckJanuvia, Janumet Xr | $311 | $94,858115 claims |
| GSKTrelegy Ellipta | $751 | $86,759122 claims |
| Aimmune Therapeutics, Inc.Zenpep | $19 | $41,29426 claims |
| BayerKerendia | $718 | $35,48042 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $340 | $35,32011 claims |
| Lilly USA, LLCMounjaro | $511 | $23,03320 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 165 nephrology providers in Kentucky.
Other nephrology in Mt Sterling
- Dawn CasterLouisville$902K
- Danny WooLouisville$427K
- Boutros El-HaddadLouisville$329K
- Javier Neyra LozanoLexington$223K
- Abdul BuridiLouisville$187K
- Sadiq AhmedLexington$140K
- Kurt SowersHazard$119K
- Nizar AttallahLouisville$113K
- Ravinder BhagrathPikeville$84K
- Shafic Abdul Wahab El HindiLouisville$45K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.